PB1902: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF TAGRAXOFUSP, A CD123-DIRECTED THERAPY, FOR THE TREATMENT OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM

Antzeko izenburuak

• P529: FIRST EUROPEAN REAL-WORLD EVIDENCE PROSPECTIVE REGISTRY OF FIRST-LINE ADULT PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH FIRST-IN-CLASS CD123-TARGETED THERAPY TAGRAXOFUSP
  nork: U. Platzbecker, et al.
  Argitaratua: (2022-06-01)
• Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm
  nork: Marlise R. Luskin, et al.
  Argitaratua: (2023-03-01)
• P521: TREATMENT OF BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM IN PEDIATRIC PATIENTS WITH TAGRAXOFUSP, A CD123-TARGETED THERAPY
  nork: N. Pemmaraju, et al.
  Argitaratua: (2022-06-01)
• P531: AN OBSERVATIONAL, MULTICENTER, RETROSPECTIVE ANALYSIS OF PATIENTS WITH BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM TREATED WITH TAGRAXOFUSP IN THE EUROPEAN EXPANDED ACCESS PROGRAM
  nork: M. Herling, et al.
  Argitaratua: (2022-06-01)
• Treatment of leptomeningeal disease in blastic plasmacytoid dendritic cell neoplasm following tagraxofusp-erzs induction
  nork: Deepak B. Vangala, et al.
  Argitaratua: (2022-04-01)